DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

Phase 1

Completed

Conditions: Solid Tumors
Advanced Malignancies

Interventions: Drug: Patupilone

First Posted Date: 2007-01-24

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT00426140

Locations: 🇺🇸
Cancer Therapy and Research Center, Institution for Drug Development, San Antonio, Texas, United States

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Cutaneous T-Cell Lymphoma

Interventions: Drug: Panobinostat

First Posted Date: 2007-01-23

Last Posted Date: 2021-08-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 139

Registration Number: NCT00425555

Locations: 🇨🇭
Novartis Investigative Site, Zürich, Switzerland
🇺🇸
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2), Atlanta, Georgia, United States
🇺🇸
Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, United States

and more 14 locations

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Valsartan + amlodipine 40/2.5 mg
Drug: Valsartan + amlodipine 40/5 mg
Drug: Valsartan + amlodipine 80/2.5 mg
Drug: Valsartan + amlodipine 80/5 mg
Drug: Valsartan 40 mg
Drug: Valsartan 80 mg
Drug: Amlodipine 2.5 mg
Drug: Placebo
Drug: Amlodipine 5 mg

First Posted Date: 2007-01-23

Last Posted Date: 2011-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1474

Registration Number: NCT00425373

Locations: 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
Drug: Everolimus + Cyclosporine
Drug: Steroids

First Posted Date: 2007-01-22

Last Posted Date: 2017-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT00425308

Locations: 🇫🇷
Novartis Investigative Site, Paris, France

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

Phase 1

Completed

Conditions: Multiple Myeloma
Breast Cancer

Interventions: Drug: Zoledronic acid

First Posted Date: 2007-01-22

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT00424983

Locations: 🇺🇸
Oncotherapeutics, West Hollywood, California, United States
🇺🇸
Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States
🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States

and more 4 locations

Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Rivastigmine transdermal patch

First Posted Date: 2007-01-17

Last Posted Date: 2014-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 859

Registration Number: NCT00423085

Locations: 🇯🇵
Novartis Investigative Site, Hokkaido region, Hokkaido, Japan

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate sodium
Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2007-01-17

Last Posted Date: 2011-06-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 81

Registration Number: NCT00423098

Locations: 🇬🇧
Novartis, Cambridge, United Kingdom
🇫🇷
Novartis Investigative Site, Paris, France

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: imatinib

First Posted Date: 2007-01-17

Last Posted Date: 2016-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT00422825

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Phase 1

Completed

Conditions: Advanced Malignancies
Tumors

Interventions: Drug: Patupilone/EPO906

First Posted Date: 2007-01-11

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00420524

Locations: 🇺🇸
Cancer Research and Treatment Center, Albuquerque, New Mexico, United States
🇺🇸
Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science, San Antonio, Texas, United States
🇺🇸
University of California San Diego/Moores Cancer Center, La Jolla, California, United States

and more 1 locations

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Phase 1

Completed

Conditions: Advanced Malignancies
Tumors

Interventions: Drug: Patupilone/EPO906

First Posted Date: 2007-01-11

Last Posted Date: 2012-01-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT00421044

Locations: 🇺🇸
University of California San Diego/Moores Cancer Center, La Jolla, California, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸
Institute for Drug Development Cancer Therapy & Research Center/The University of Texas Health Science Center, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy